ArticleClinical cancer research : an official journal of the American Association for Cancer Research2015
Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02730923 (A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014), which is not on this map. Cited by 101 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma
Who cites it
101 citing papers in PubMed, 3 syntheses or guidelines pooled it, 184 citations in OpenAlex.
- Distant Metastasis in Colorectal Cancer Patients-Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review.International journal of molecular sciences · 2020Pooled it
- Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.BMC cancer · 2019Pooled it
- K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis.Medical oncology (Northwood, London, England) · 2016Pooled it
- Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.Cancer discovery · 2017Trial
- Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.Nature communications · 2016Trial
- Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer.Scientific reports · 2015Trial
- Exploring the mechanism of action of abemaciclib in breast cancer through circulating chromatin fragments.Communications medicine · 2026Article
- Circulating cell-free DNA and circulating tumor DNA as a prognostic biomarker in metastatic spine disease, is there a role?Neurosurgical review · 2026Review
- Blood and urine-based biomarkers in prostate cancer: Current advances, clinical applications, and future directions.The journal of liquid biopsy · 2025Review
- Liquid Biopsy in Solid Tumours: An Overview.Cytopathology : official journal of the British Society for Clinical Cytology · 2025Review
- Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications.The journal of liquid biopsy · 2023Review
- Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer.NPJ breast cancer · 2023Review
- Assessment of Tissue Adequacy by EBUS in Conjunction with PET Scan and Operator's Experience.Clinics and practice · 2022Article
- Current and Future Perspectives of Cell-Free DNA in Liquid Biopsy.Current issues in molecular biology · 2022Review
- NucPosDB: a database of nucleosome positioning in vivo and nucleosomics of cell-free DNA.Chromosoma · 2022Article
- Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review.Cancer metastasis reviews · 2022Review
- Recent Developments of Circulating Tumor Cell Analysis for Monitoring Cutaneous Melanoma Patients.Cancers · 2022Review
- Cell-free DNA analysis in current cancer clinical trials: a review.British journal of cancer · 2022Review
- Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.British journal of cancer · 2022Article
- What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib.Frontiers in oncology · 2022Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 4 institutions in 3 countries.
Funding
Abstract
purposeWe evaluated whether next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA) could be used for patient selection and as a tumor clone response biomarker in patients with advanced cancers participating in early-phase clinical trials of targeted drugs. EXPERIMENTAL
designPlasma samples from patients with known tumor mutations who completed at least two courses of investigational targeted therapy were collected monthly, until disease progression. NGS was performed sequentially on the Ion Torrent PGM platform.
resultscfDNA was extracted from 39 patients with various tumor types. Treatments administered targeted mainly the PI3K-AKT-mTOR pathway (n = 28) or MEK (n = 7). Overall, 159 plasma samples were sequenced with a mean sequencing coverage achieved of 1,685X across experiments. At trial initiation (C1D1), 23 of 39 (59%) patients had at least one mutation identified in cfDNA (mean 2, range 1-5). Out of the 44 mutations identified at C1D1, TP53, PIK3CA and KRAS were the top 3 mutated genes identified, with 18 (41%), 9 (20%), 8 (18%) different mutations, respectively. Out of these 23 patients, 13 received a targeted drug matching their tumor profile. For the 23 patients with cfDNA mutation at C1D1, the monitoring of mutation allele frequency (AF) in consecutive plasma samples during treatment with targeted drugs demonstrated potential treatment associated clonal responses. Longitudinal monitoring of cfDNA samples with multiple mutations indicated the presence of separate clones behaving discordantly. Molecular changes at cfDNA mutation level were associated with time to disease progression by RECIST criteria.
conclusionsTargeted NGS of cfDNA has potential clinical utility to monitor the delivery of targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.